SkyePharma cuts plant staff by a third; Dr Reddy's forecasts 10% sales growth;

> SkyePharma said it plans to cut its 120-strong workforce at a manufacturing plant in Lyon, France, by one-third, following a 10 percent reduction of the staffing at its R&D facility in Muttenz, Switzerland. Release

> Plans by Europe's biggest drugs distributor, Celesio, to set up a pharmacy chain in its home market of Germany hinge on a European court ruling on Tuesday. Report

> Indian drug maker Dr. Reddy's Laboratories expects revenue growth of 10 percent in the fiscal year to March 2010 because of new product launches, its chief executive officer said. Report

> Cell Therapeutics said it's closing its operations in Bresso, Italy, and has reached agreement with the employee union there regarding a severance package for 56 people. Report

> GlaxoSmithKline took another step to bolster its early-stage pipeline of cancer drugs by signing a deal worth up to $370 million with privately held British biotech group Oxford BioTherapeutics. Release l Report

> Japan's Takeda Pharmaceutical has signed a deal to snap up IDM Pharma for $2.64 a share, or about $70 million. Report

> Xconomy reports that GlaxoSmithKline has spun-off Tempero Pharmaceuticals from GSK's Immuno-Inflammation Centre of Excellence in Drug Discovery. Report

> New York City council members, Senator Tom Duane (D-NY) and Assemblyman Mark Weprin (D-NY) are urging legislators to back a bill that would offer $3 million a year in tax breaks. Report

> The once high-flying diagnostic company Nanogen has filed for Chapter 11 bankruptcy protection, saying that it plans to sell off almost all its assets to French company Elitech Group for $25.7 million. Report

> Less than a month after announcing an $8 million closing, San Diego, CA-based start-up Anaphore has pulled in another $13 million and three new investors. Report

> GlobeImmune will receive $40 million up front in a deal with Celgene that could be worth up to $500 million. The two companies have entered into a worldwide strategic collaboration for the discovery, development and commercialization of cancer therapies. Report

And Finally... Taking a DHEA supplement combined with vitamin D and calcium can significantly improve spinal bone density in older women, a new study found. Release

Suggested Articles

Horizon Therapeutics has notched an FDA approval for its rare eye disease med Tepezza (teprotumumab), a possible blockbuster drug in the making.

Eli Lilly has a pipeline stuffed with a host of assets and has decided it needs a new injectable drug and device plant to manufacture some of them.

After Clovis’ Rubraca snagged an FDA boost in prostate cancer last week, AZ and Merck’s rival Lynparza has matched it with a boost of its own.